- Gold pares early-week losses despite latest pullback from $1,883.93.
- Covid recalls activity restrictions in US states, Fed Chair Powell warns about vaccine hopes.
- Trade, political tensions also join the line to weigh the risks.
- Aussie PM’s likely hint for vaccine, reopening can entertain Asian traders amid a light calendar.
Gold extends the previous day’s corrective recovery while picking up the bids near $1,877 during the early Friday’s Asian session. In doing so, the yellow metal consolidates the biggest losses in three months, marked on Monday, amid fresh risks emanating from the coronavirus (COVID-19), trade and political frontiers.
Vaccine hopes aren’t enough to restore economics…
Although Pfizer, Moderna and Chinese pharmaceuticals are trying their best to find the cure to the deadly virus, Federal Reserve Chairman Jerome Powell’s hint to not be too optimistic about the cure’s economic impact cooled down the earlier positive market sentiment. This comes at a time when the US and Europe record all-time high cases, which in turn pushes Chicago to join New Zealand in announcing the local lockdowns.
Traders have also heard about China after multiple days of silence relating to the term. The reason could be the US warning to sanction Beijing over the Hong Kong crackdown while also showing readiness to clamp down the American investments in Chinese companies. Further, the dragon nation’s ban on Victorian timber logs becomes an additional reason for the Asian major’s media highlight.
Against this backdrop, US equities trim the latest gains while bond yields slump below 0.90% with the heaviest declines in a week.
Moving on, gold traders await fresh signals over the virus spread and/or vaccine for near-term direction. As a result, the scheduled meeting of the Australian policymakers, which ABC News cites carrying the vaccine news and reopening announcements, becomes the key.
Gold regains its stand above 100-day EMA, currently around $1,875, after declining to the lowest since September 28 on Monday. The pullback currently eyes a 50-day EMA level near $1,900 while bears remain cautious unless witnessing a downside break of September low around $1,848.
Additional important levels
|Today last price||1877.12|
|Today Daily Change||13.26|
|Today Daily Change %||0.71%|
|Today daily open||1863.86|
|Previous Daily High||1884.51|
|Previous Daily Low||1856.34|
|Previous Weekly High||1960.4|
|Previous Weekly Low||1873.52|
|Previous Monthly High||1933.3|
|Previous Monthly Low||1860|
|Daily Fibonacci 38.2%||1867.1|
|Daily Fibonacci 61.8%||1873.75|
|Daily Pivot Point S1||1851.96|
|Daily Pivot Point S2||1840.07|
|Daily Pivot Point S3||1823.79|
|Daily Pivot Point R1||1880.13|
|Daily Pivot Point R2||1896.41|
|Daily Pivot Point R3||1908.3|
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.